Keryx looks to label expansion to drive Auryxia

February 8, 2017 Christoph Graener

After a stuttering launch and relaunch, Keryx Biopharmaceuticals CEO Greg Madison revealed to Mike Ward, Informa Pharma Intelligence’s insights global director of content, that Auryxia prescriptions picked up in 4Q 2016. The company plans to expand the drug’s label to treat iron deficiency in pre-dialysis patients while searching for additional nephrology assets during 2017.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Greg Madison – CEO, Keryx

Previous Article
Shield pilots ironclad specialty future with Feraccru

Bolstered with a successful launch in Germany and the UK of its anemia treatment Feraccru, Shield Therapeut...

Next Article
Payer environment will impact biopharma prospects in 2017

Michael Hay, head of Informa Pharma Intelligence Products, shares his thoughts on how shareholder pressure ...